Jun 29, 2024

Hey everyone! I’ve got some exciting healthcare news to share with you. First off, there’s a lot of talk about the future of Alzheimer’s treatments. Despite the limited effectiveness and potential side effects of the latest class of drugs, there’s still hope on the horizon. Eli Lilly’s drug, donanemab, could soon become the third anti-amyloid monoclonal antibody to receive some kind of FDA approval. An FDA advisory committee recently voted in support of donanemab, concluding that its benefits outweigh its risks.

In other news, the presidential debate was overshadowed by errors and falsehoods, especially when it came to discussions about healthcare. The U.S. Supreme Court also ruled against a settlement deal that would have allowed the owners of Purdue Pharma to pay $6 billion to victims of the opioid epidemic, in exchange for immunity from future lawsuits.

Lastly, there’s still hope for the FDA approval of MDMA therapy for post-traumatic stress disorder. Despite some setbacks, there’s optimism that the FDA may still consider the drug’s application in the future.

Overall, there’s a lot of progress and potential in the healthcare industry, and I can’t wait to see what the future holds. Stay positive and keep spreading good health vibes!

Summy

Stay Well!